Nykode Therapeutics AS (NYKD.OL)
NOK 2.59
(15.42%)
NOK 2.59
(15.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -41.74 Million USD | -18.42% |
| 2022 | -52.74 Million USD | -545.29% |
| 2021 | -10.25 Million USD | -104.42% |
| 2020 | 181.25 Million USD | 1495.4% |
| 2019 | -12.53 Million USD | -57.93% |
| 2018 | -7.6 Million NOK | -80.0% |
| 2017 | -3.8 Million NOK | -72.11% |
| 2016 | -25.07 Million NOK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.86 Million USD | 43.95% |
| 2024 Q1 | -160.28 Million USD | -34.2% |
| 2023 FY | - USD | -18.42% |
| 2023 Q2 | -123.21 Million USD | 16.01% |
| 2023 Q3 | -145.33 Million USD | -17.95% |
| 2023 Q4 | -180.75 Million USD | -24.37% |
| 2023 Q1 | -146.71 Million USD | 0.99% |
| 2022 Q2 | -95.24 Million NOK | -30.2% |
| 2022 FY | - USD | -545.29% |
| 2022 Q4 | -148.17 Million USD | 24.52% |
| 2022 Q3 | -196.32 Million NOK | -106.13% |
| 2022 Q1 | -73.15 Million NOK | -158.73% |
| 2021 Q4 | 124.55 Million NOK | 233.84% |
| 2021 FY | - USD | -104.42% |
| 2021 Q3 | -93.06 Million NOK | 0.0% |
| 2020 FY | - USD | 1495.4% |
| 2019 FY | - USD | -57.93% |
| 2018 FY | - NOK | -80.0% |
| 2017 FY | - NOK | -72.11% |
| 2016 FY | - NOK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arctic Bioscience AS | -37.78 Million NOK | -10.469% |
| Aqua Bio Technology ASA | -16.56 Million NOK | -151.94% |
| ArcticZymes Technologies ASA | 31.64 Million NOK | 231.905% |
| BerGenBio ASA | -191.8 Million NOK | 78.238% |
| Hofseth BioCare ASA | -70.6 Million NOK | 40.88% |
| PCI Biotech Holding ASA | -22.22 Million NOK | -87.832% |
| Thor Medical ASA | -6.82 Million NOK | -511.217% |
| Ultimovacs ASA | -214.85 Million NOK | 80.572% |